Fundamental Analysis of Brainstorm Cell Therapeutics Inc - Growth / Value Index
BCLI - Valuation Highlights
Valuation Analysis
Tsr Value Index - Very Poor Score of 5.00
Book Value in last 3 years is trending down
Book value is negative
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | -1.49 | -1.18 | -71.35 % | |
| Price to Book | -4.17 | -2.91 | 47.62 % | -4.73 |
| Price to Sales | 117.46 | 0 | 0 % | |
| Enterprise Value to EBITDA Multiple | -1.44 | -1.16 | -63.39 % |
BCLI - Profitability Highlights
Profitability Analysis
During the past twelve months, the company has given a strong Net Margin of 5012.24%
All key Trailing Twelve Months Margin growing by 15 %
Reasonable Dividend Yield of 3.60 %
Annual Net Profit in last 3 years is trending up
EBITDA is continuously increasing for last 3 Years
Tsr Profitability Index - Poor Score of 30.77
Piotroski F Score - Very Poor Value of 0.0
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 0 | 0 | 0 % | 0 |
| Return On Asset | -231.00 | -720.31 | -150.75 % | -132.56 |
| Net Profit Margin | -7878.57 | 0 | 0 % | 0 |
| Operating Profit Margin | -10576.62 | 0 | 0 % | 0 |
| EBITDA Margin | -13691.56 | 0 | 0 % | 0 |
Highlights
| Market Cap | 31163.91 K |
| Enterprise Value | 30466.91 K |
| Price/Book TTM | -4.17 |
| Outstanding Share | 68341.90 K |
| Float/ Outstanding Share | 88.96% |
| Dividend Yield | 3.60 % |
Share Holding
Guru Numbers
| Price/Graham No | 0 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 0 |
| Altman Z Score | -152.07 |
| Sloan Ratio | 2.25 |
| Peter Lynch Fair Value | 0 |
BCLI - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Very Poor Score of 5.00
Annual sales in last 3 years is trending down
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 154000 | % | % |
| Gross Profit | 23000.00 | 7.02 % | % |
| EBITDA | -21085.00 K | 33.31 % | % |
| Net Profit | -12133.00 K | 31.49 % | % |
| EPS | -0.306 | 41.64 % | NA |
BCLI - Stability Highlights
Stability Analysis
Paid More Than 50% of Debt, Heading towards debt free
Tsr Stability Index - Very Poor Score of 5.00
Altman Z Score of -152.41 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | -0.089 | 81.14 % | -0.124 |
| Cash Ratio | 0.167 | -50.83 % | |
| Quick Ratio | 0 | 0 % | 0.243 |
| Shareholders Equity | -292.64 | -720.26 % | |
| Debt to EBITDA | -0.0369 | 36.63 % |
Historical Valuation Ratios of Brainstorm Cell Therapeutics Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Brainstorm Cell Therapeutics Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Brainstorm Cell Therapeutics Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Brainstorm Cell Therapeutics Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)